Literature DB >> 12067996

Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.

Laura Soucek1, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, Sergio Nasi.   

Abstract

The Myc basic helix-loop-helix zipper domain determines dimerization with Max and binding to the DNA E-box, both of which play a critical role in Myc regulation of growth, proliferation, tumorigenesis, and apoptosis. The mutant basic helix-loop-helix zipper domain, Omomyc, dimerizes with Myc, sequestering it in complexes unable to bind the E-box, and so acting as a potential dominant negative. Consistent with this, Omomyc reverses Myc-induced cytoskeletal disorganization in C2C12 myoblasts. Surprisingly, however, Omomyc strongly potentiates Myc-induced apoptosis in a manner dependent on Myc expression level. Expression analysis of known Myc target genes indicates that Omomyc inhibits transcriptional activation but enhances repression. These findings suggest that Omomyc can selectively trigger apoptosis in cells overexpressing Myc, possibly through the transcriptional repression of specific genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067996

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  76 in total

Review 1.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  Myc: the beauty and the beast.

Authors:  Amanda R Wasylishen; Linda Z Penn
Journal:  Genes Cancer       Date:  2010-06

Review 4.  Therapeutic strategies to inhibit MYC.

Authors:  Michael R McKeown; James E Bradner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

5.  An "-omycs" Toolbox to Work with MYC.

Authors:  Jonathan Whitfield; Laura Soucek
Journal:  Methods Mol Biol       Date:  2021

6.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

Review 7.  The ups and downs of Myc biology.

Authors:  Laura Soucek; Gerard I Evan
Journal:  Curr Opin Genet Dev       Date:  2009-12-03       Impact factor: 5.578

Review 8.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

9.  c-Myc and cancer metabolism.

Authors:  Donald M Miller; Shelia D Thomas; Ashraful Islam; David Muench; Kara Sedoris
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

10.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Authors:  Laura Soucek; Jonathan R Whitfield; Nicole M Sodir; Daniel Massó-Vallés; Erika Serrano; Anthony N Karnezis; Lamorna Brown Swigart; Gerard I Evan
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.